Giancarlo Castaman
#142,292
Most Influential Person Now
Researcher
Giancarlo Castaman's AcademicInfluence.com Rankings
Download Badge
Physics
Giancarlo Castaman's Degrees
- PhD Physics University of Milan
- Masters Physics University of Milan
- Bachelors Physics University of Milan
Why Is Giancarlo Castaman Influential?
(Suggest an Edit or Addition)Giancarlo Castaman's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Epidemiological investigation of the prevalence of von Willebrand's disease. (1987) (942)
- A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD) (2006) (509)
- Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). (2007) (384)
- The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study (2005) (324)
- Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. (2009) (240)
- Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. (1990) (234)
- Congenital absence of the inferior vena cava: a rare risk factor for idiopathic deep-vein thrombosis (2001) (229)
- Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. (2003) (210)
- Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. (2018) (207)
- Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. (2008) (192)
- Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. (2013) (189)
- A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. (1997) (173)
- Detection of New Polymorphic Markers in the Factor V Gene: Association with Factor V Levels in Plasma (1996) (171)
- Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. (1998) (169)
- Principles of care for the diagnosis and treatment of von Willebrand disease (2013) (166)
- Clinical Manifestations and Management of Inherited Thrombophilia: Retrospective Analysis and Follow-up after Diagnosis of 238 Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S (1994) (161)
- Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD) (2008) (160)
- Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). (2008) (159)
- Guidelines for the diagnosis and management of von Willebrand disease in Italy (2002) (152)
- Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. (2016) (149)
- The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. (2000) (140)
- Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. (1996) (137)
- Early haemorrhagic morbidity and mortality during remission induction with or without all‐trans retinoic acid in acute promyelocytic leukaemia (2000) (130)
- Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. (1992) (129)
- Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients (2012) (123)
- von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers. (1988) (119)
- Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation (2011) (119)
- Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD (2006) (117)
- Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. (2015) (116)
- Thrombosis during Pregnancy and Surgery in Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S (1994) (116)
- The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. (2014) (116)
- von Willebrand factor regulation of blood vessel formation. (2018) (111)
- Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. (2008) (110)
- von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery (2007) (109)
- Current Diagnostic and Therapeutic Approaches to Patients with Acquired von Willebrand Syndrome: A 2013 Update (2013) (104)
- Inconsistency of Association between Type 1 von Willebrand Disease Phenotype and Genotype in Families Identified in an Epidemiological Investigation (1999) (103)
- Characterization of the Genetic Defects in Recessive Type 1 and Type 3 von Willebrand Disease Patients of Italian Origin (1998) (102)
- Cysteine‐mutations in von Willebrand factor associated with increased clearance (2005) (101)
- The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype (2008) (101)
- Markers of Procoagulant Imbalance in Patients with Inherited Thrombophilic Syndromes (1992) (98)
- Pharmacokinetics and safety of fibrinogen concentrate (2009) (97)
- Characterization of a novel bleeding disorder with isolated prolonged bleeding time and deficiency of platelet microvesicle generation (1997) (97)
- VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. (2013) (94)
- A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype (1997) (92)
- Prospective Multicenter Study on Subcutaneous Concentrated Desmopressin for Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A (1996) (92)
- Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. (1989) (91)
- How I treat von Willebrand disease. (2009) (91)
- How to estimate bleeding risk in mild bleeding disorders (2007) (91)
- Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia (2002) (86)
- Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results. (2019) (85)
- Evidence-based recommendations on the treatment of von Willebrand disease in Italy. (2009) (83)
- Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues (2004) (82)
- Bleeding scores in inherited bleeding disorders: clinical or research tools? (2008) (77)
- Replacement Therapy with Virus—Inactivated Plasma Concentrates in von Willebrand Disease (1992) (77)
- Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease. (1991) (76)
- Von Willebrand Disease Type 2M “Vicenza” in Italian and German Patients: Identification of the First Candidate Mutation (G3864A; R1205H) in 8 Families (2000) (76)
- Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. (2007) (75)
- Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study (2006) (73)
- Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). (1999) (72)
- Coinheritance of the HR2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R506Q (Factor V Leiden) (1999) (71)
- Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. (2008) (70)
- Assessing bleeding in von Willebrand disease with bleeding score. (2007) (69)
- Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM‐1VWD study (2009) (66)
- Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1VWD) (2007) (64)
- Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V (1997) (64)
- Deep intronic variations may cause mild hemophilia A (2011) (63)
- Patients With Type 3 Severe von Willebrand Disease Are Not Protected Against Atherosclerosis: Results From a Multicenter Study in 47 Patients (2004) (63)
- Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. (2014) (60)
- Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A (2009) (58)
- Clinical manifestations and management of Gaucher disease. (2015) (58)
- Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A (2015) (57)
- Bleeders, bleeding rates, and bleeding score (2013) (57)
- Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. (2015) (57)
- Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors (2012) (57)
- Desmopressin for the treatment of haemophilia (2007) (56)
- Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease (1995) (56)
- Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. (2019) (56)
- Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening (1993) (55)
- The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis. (2003) (55)
- The Factor VIII/Von Willebrand Factor Ratio Discriminates between Reduced Synthesis and Increased Clearance of Von Willebrand Factor (2002) (54)
- Type I factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain. (1996) (54)
- European retrospective study of real‐life haemophilia treatment (2017) (52)
- Pregnancy and delivery in women with von Willebrand’s disease and different von Willebrand factor mutations (2010) (52)
- Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders (2017) (51)
- Molecular diversity and thrombotic risk in protein S deficiency: The PROSIT study (2005) (50)
- Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. (2011) (49)
- Autosomal dominant type 1 von Willebrand disease due to G3639T mutation (C1130F) in exon 26 of von Willebrand factor gene: description of five Italian families and evidence for a founder effect (2000) (48)
- Congenital von Willebrand disease type I: definition, phenotypes, clinical and laboratory assessment. (2001) (48)
- Hemophilia A and B: molecular and clinical similarities and differences (2019) (46)
- IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. (2015) (45)
- How I treat type 2 variant forms of von Willebrand disease. (2015) (45)
- Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. (2019) (44)
- Low prevalence of thrombophilia coagulation defects in patients with deep vein thrombosis of the upper limbs (1997) (44)
- Characterization of two cases of acquired transitory von willebrand syndrome with ciprofloxacin: Evidence for heightened proteolysis of von willebrand factor (1995) (44)
- Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors (2019) (44)
- The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: a study of 34 patients with various subtypes of type I von Willebrand disease (1994) (43)
- Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance (2011) (43)
- Treatment of von Willebrand disease. (2005) (42)
- TT virus contaminates first-generation recombinant factor VIII concentrates. (2001) (42)
- The impact of bleeding history, von Willebrand factor and PFA–100® on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM‐1VWD (2010) (42)
- A bleeding disorder characterised by isolated deficiency of platelet microvesicle generation (1996) (41)
- The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH (2018) (41)
- Pregnancy and delivery in women with von Willebrand disease (2019) (41)
- Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance (2009) (41)
- An Additional Unique Candidate Mutation (G2470A; M740I) in the Original Families with von Willebrand Disease Type 2 M Vicenza and the G3864A (R1205H) Mutation (2000) (40)
- Von Willebrand Factor Antigen Is Less Sensitive than Ristocetin Cofactor for the Diagnosis of Type I von Willebrand Disease -Results Based on an Epidemiological Investigation (1990) (40)
- Effectiveness of high‐dose intravenous immunoglobulin in a case of acquired von willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate (1992) (40)
- Platelet von willebrand factor abnormalities in myeloproliferative syndromes (1995) (39)
- Clinical usefulness of desmopressin for prevention of surgical bleeding in patients with symptomatic heterozygous factor XI deficiency (1996) (39)
- Hyper‐responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra‐platelet von Willebrand factor (1988) (39)
- Molecular mechanisms of type II factor XIII deficiency: novel Gly562-Arg mutation and C-terminal truncation of the A subunit cause factor XIII deficiency as characterized in a mammalian expression system. (1998) (38)
- Gestational thrombocytopenia: a prospective study. (1997) (37)
- A novel candidate mutation (Arg611→ His) in type I‘platelet discordant’von Willebrand's disease with desmopressin‐induced thrombocytopenia (1995) (37)
- Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease. (1989) (36)
- A common 253‐kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3 (2007) (36)
- Inhibitors in Hemophilia B (2018) (36)
- Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery (2018) (36)
- Platelet Adhesion to Collagen in Subtypes of Type I von Willebrand’s Disease Is Dependent on Platelet von Willebrand Factor (1990) (35)
- Topologically equivalent mutations causing dysfunctional coagulation factors VII (294Ala-->Val) and X (334Ser-->Pro). (1994) (35)
- Mutations in the erythropoietin receptor gene are not a common cause of Diamond-Blackfan anemia. (1996) (35)
- Mutation pattern in clinically asymptomatic coagulation factor VII deficiency (1996) (35)
- Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia. (1990) (35)
- Changes of von Willebrand Factor during Pregnancy in Women with and without von Willebrand Disease (2013) (34)
- Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. (2020) (34)
- Acquired haemophilia: experience of two Italian centres with 17 new cases (1997) (34)
- Successful pregnancy in a woman with congenital factor XIII deficiency treated with substitutive therapy (1987) (34)
- High levels of histidine-rich glycoprotein and thrombotic diathesis. Report of two unrelated families. (1993) (33)
- Prophylaxis of bleeding episodes and surgical interventions in patients with rare inherited coagulation disorders. (2008) (32)
- Inhibitors in haemophilia B: the Italian experience (2013) (31)
- Von Willebrand's disease: clinical management (2006) (31)
- The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia. (1994) (30)
- Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A. (2014) (30)
- Central nervous system bleeding in patients with rare bleeding disorders (2012) (30)
- Obstetric complications and pregnancy-related venous thromboembolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation (2012) (30)
- Clinical pharmacokinetics of a placenta‐derived factor XIII concentrate in type I and type II factor XIII deficiency (1991) (29)
- The benefits of prophylaxis in patients with hemophilia B (2018) (29)
- Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H‐M740I) defect (2006) (29)
- Acquired transitory von Willebrand syndrome with ciprofloxacin (1994) (29)
- F8 gene mutation profile and ITT response in a cohort of Italian haemophilia A patients with inhibitors (2007) (29)
- A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high-dose immunoglobulins and anti-D immunoglobulins. (1992) (29)
- Mutations in the thrombomodulin gene are rare in patients with severe thrombophilia (2002) (29)
- Polycythemia vera and essential thrombocythemia in young patients. (1993) (29)
- Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation. (1990) (28)
- Simultaneous genotyping of coagulation factor XI type II and type III mutations by multiplex real-time polymerase chain reaction to determine their prevalence in healthy and factor XI-deficient Italians (2008) (27)
- Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis (2014) (27)
- Fulminant sepsis in adults splenectomized for idiopathic thrombocytopenic purpura. (1992) (27)
- von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels (2010) (27)
- Acquired plasma factor XIII deficiencies. (1993) (26)
- The bleeding time in normal subjects is mainly determined by platelet von Willebrand factor and is independent from blood group. (1992) (26)
- Molecular characterization of two novel mutations causing factor XI deficiency: A splicing defect and a missense mutation responsible for a CRM+ defect (2008) (26)
- Desmopressin and type II B von Willebrand disease (1996) (26)
- Phenotypic APC Resistance in Carriers of the A20210 Prothrombin Mutation Is Associated with an Increased Risk of Venous Thrombosis (2001) (26)
- Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. (2010) (26)
- von Willebrand’s disease diagnosis and laboratory issues (2010) (26)
- A novel factor V null mutation detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an asymptomatic unrelated subject. (1998) (26)
- Platelet von Willebrand factor assay: results using two methods for platelet lysis. (1990) (26)
- Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor resulting in autosomal recessive severe von Willebrand disease (2006) (26)
- Pregnancy in Women with Type 1 von Willebrand Disease Caused by Heterozygosity for von Willebrand Factor Mutation C1130F (2000) (25)
- Total Hip Arthroplasty in Haemophilic Patients with Modern Cementless Implants. (2015) (24)
- Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease (2013) (24)
- Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (1997) (24)
- ABO blood group also influences the von Willebrand factor (VWF) antigen level in heterozygous carriers of VWF null alleles, type 2N mutation Arg854GIn, and the missense mutation Cys2362Phe. (2002) (24)
- Hematological manifestations and complications of Gaucher disease (2016) (24)
- Association of factor V deficiency with factor V HR2. (2004) (23)
- Severe spontaneous arterial thrombotic manifestations in patients with inherited hypo‐ and afibrinogenemia (2009) (23)
- F8 mRNA studies in haemophilia A patients with different splice site mutations (2010) (23)
- Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. (2009) (23)
- A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. (2019) (22)
- Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A (2006) (22)
- Missense or splicing mutation? The case of a fibrinogen Bbeta-chain mutation causing severe hypofibrinogenemia. (2004) (22)
- Multimeric pattern of plasma and platelet von willebrand factor is normal in uremic patients (1993) (22)
- Risk of bleeding and thrombosis in inherited qualitative fibrinogen disorders (2019) (22)
- Alterations of mRNA processing and stability as a pathogenic mechanism in von Willebrand factor quantitative deficiencies (2010) (21)
- Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol. (1993) (21)
- Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype (2010) (21)
- Congenital afibrinogenemia: Successful prevention of recurrent hemoperitoneum during ovulation by oral contraceptive (1995) (21)
- Inherited abnormalities of blood coagulation in juvenile stroke. A case‐control study (1997) (21)
- Treatment of von Willebrand disease with FVIII/VWF concentrates. (2011) (21)
- Thrombosis in Subjects with Homozygous and Heterozygous Factor XII Deficiency (1992) (20)
- Acute renal failure after high-dose intravenous immune globulin in a patient with idiopathic thrombocytopenic purpura. (1993) (20)
- Spectrum of mutations in Albanian patients with haemophilia A: identification of ten novel mutations in the factor VIII gene (2007) (20)
- Heterogeneity of Activated Protein C Resistance Phenotype in Subjects with Compound Heterozygosity for HR2 Haplotype and FV Leiden Mutation (R506Q) in Factor V Gene (2000) (20)
- Ribosome readthrough accounts for secreted full‐length factor IX in hemophilia B patients with nonsense mutations (2012) (20)
- Pseudo‐exon activation caused by a deep‐intronic mutation in the fibrinogen γ‐chain gene as a novel mechanism for congenital afibrinogenaemia (2007) (20)
- The VITA Project: Heritability of Resistance to Activated Protein C (2000) (19)
- The elusive pathogenesis of von Willebrand disease Vicenza. (2002) (19)
- A comparison between two semi‐quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease (2011) (19)
- Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks (2018) (18)
- Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia. (1993) (18)
- Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma. (2002) (18)
- Fibrinolytic studies in 13 unrelated families with factor XII deficiency. (1991) (18)
- Reduced von Willebrand factor secretion is associated with loss of Weibel–Palade body formation (2012) (18)
- A type II mutation (Glu117stop), induction of allele-specific mRNA degradation and factor XI deficiency. (2005) (18)
- High-dose dexamethasone in adult refractory idiopathic thrombocytopenic purpura. (1996) (18)
- Recombinant FXIII (rFXIII-A 2 ) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency (2018) (18)
- No evidence for a direct effect of von Willebrand factor's ABH blood group antigens on von Willebrand factor clearance (2015) (18)
- Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glul02Lys) in the second EGF‐like domain (1995) (17)
- Von Willebrand Disease: Epidemiology (2007) (17)
- Identification and computationally‐based structural interpretation of naturally occurring variants of human protein C (2007) (17)
- Pregnancy and delivery in patients with homozygous or heterozygous R854Q type 2N von Willebrand disease (2005) (17)
- Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B (2019) (17)
- Symptomatic type II protein C deficiency caused by a missense mutation (Gly 381 → Ser) in the substrate‐binding pocket (1993) (17)
- Alpha (p55) and beta (p75) chains of the interleukin-2 receptor are expressed by AML blasts. (1993) (16)
- Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality (2016) (16)
- VON WILLEBRAND FACTOR ABNORMALITIES IN TWO PATIENTS WITH URAEMIA (1988) (16)
- A novel family with recessive von Willebrand disease due to compound heterozygosity for a splice site mutation and a missense mutation in the von Willebrand factor gene. (2002) (16)
- Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations. (2017) (16)
- Desmopressin‐induced thrombocytopenia in type i platelet discordant von willebrand disease (1993) (15)
- The spectrum of factor XI deficiency in Italy (2014) (15)
- Characterization of the neutralizing anti‐emicizumab antibody in a patient with hemophilia A and inhibitor (2020) (15)
- Management of thrombocytopenia in cancer. (2018) (15)
- Coinheritance of the HR 2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R 506 Q ( Factor V Leiden ) (1999) (15)
- Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study (2020) (15)
- Hemophilia A and B: molecular and clinical characteristics of similar, but different diseases. (2019) (14)
- Comorbidities in persons with haemophilia aged 60 years or more compared with age‐matched people from the general population (2018) (14)
- The A20210 allele in the prothrombin gene enhances the risk of venous thrombosis in carriers of inherited protein S deficiency (2000) (14)
- Novel Y283C mutation of the A subunit for coagulation factor XIII: molecular modelling predicts its impaired protein folding and dimer formation (2001) (14)
- Clinical relevance of isolated prolongation of the activated partial thromboplastin time in a cohort of adults undergoing surgical procedures. (2017) (14)
- EDTA‐dependent pseudothrombocytopenia (1992) (14)
- Prevalence of type 2b ‘Malmö/New York’ von Willebrand disease in Italy: the role of von Willebrand factor gene conversion (2008) (14)
- Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates (2019) (14)
- Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis (1999) (14)
- Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET (2020) (14)
- Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A (2016) (13)
- Long-lasting remission after high-dose intravenous immunoglobulins in a case of relapsing thrombotic thrombocytopenic purpura. (1991) (13)
- Heightened proteolysis of the von Willebrand factor subunit in patients with von Willebrand disease hemizygous or homozygous for the C2362F mutation (2000) (13)
- Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. (2013) (13)
- A new variant of von Willebrand disease (type II I) with a normal degree of proteolytic cleavage of von Willebrand factor. (1992) (13)
- Autosomal recessive von Willebrand disease associated with compound heterozygosity for a novel nonsense mutation (2908 del C) and the missense mutation C2362F: Definite evidence for the non‐penetrance of the C2362F mutation (2007) (13)
- Blood group significantly influences von Willebrand factor increase and half‐life after desmopressin in von Willebrand disease Vicenza (2010) (12)
- Identification of three candidate mutations causing type IIA von Willebrand disease using a rapid, nonradioactive, allele-specific hybridization method (1993) (12)
- Consistency of responses to separate desmopressin infusions in patients with storage pool disease and isolated prolonged bleeding time. (1993) (12)
- A proteomic analysis of changes in prothrombin and plasma proteins associated with the G20210A mutation (2004) (12)
- Immunophenotypic and genotypic characterization of B-cell chronic lymphocytic leukemia patients from northern Italy. (1993) (12)
- Bβ 14 Arg→Cys variant dysfibrinogen and its association with thrombosis (2005) (12)
- The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors. (2017) (12)
- Sustained high trough factor IX activity levels with continued use of rIX‐FP in adult and paediatric patients with haemophilia B (2019) (11)
- Effect of the VWF promoter (GT)n repeat and single‐nucleotide polymorphism c.‐2527G>A on circulating von Willebrand factor levels under normal conditions (2011) (11)
- High rate of sustained virological response with direct‐acting antivirals in haemophiliacs with HCV infection: A multicenter study (2019) (11)
- TNF-α/TNF-R System May Represent a Crucial Mediator of Proliferative Synovitis in Hemophilia A (2019) (11)
- The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology (2021) (11)
- Advances in the diagnosis and management of type 1 von Willebrand disease (2011) (11)
- New development in von Willebrand disease (2013) (11)
- Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres (2015) (10)
- The Genetic Defect of Type I von Willebrand Disease “Vicenza” Is Linked to the von Willebrand Factor Gene (1993) (10)
- An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS‐VWF study (2018) (10)
- Inhibitors in Nonsevere Hemophilia A: What Is Known and Searching for the Unknown (2018) (10)
- Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A‐LONG and Kids A‐LONG Studies (2017) (10)
- Multiplex Amplification and Fluorimetric Detection of Short Tandem Repeats for Mixed Chimerism After Bone Marrow Transplant (2003) (10)
- The factor VIII treatment history of non‐severe hemophilia A (2020) (10)
- Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients. (2007) (10)
- Thrombin potential and traditional coagulation assay: are they useful in exploring recurrent pregnancy loss risk? (2017) (9)
- A new Italian family with severe prekallikrein deficiency. Desmopressin-induced fibrinolysis and coagulation changes in homozygous and heterozygous members (1990) (9)
- A novel G-to-A mutation in the intron-N of the protein S gene leading to abnormal RNA splicing in a patient with protein S deficiency. (2003) (9)
- Second interim analysis results from the STASEY trial: A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors (2021) (9)
- Congenital hypofibrinogenemia associated with novel heterozygous fibrinogen Bβ and γ chain mutations (2008) (9)
- Risk of thrombosis in cancer and the role of supportive care (transfusion, catheters, and growth factors). (2016) (9)
- Molecular characterization of five Italian families with inherited severe factor XIII deficiency (2007) (9)
- Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders? (1993) (9)
- Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE) (2018) (9)
- Clinical effectiveness of desmopressin in a case of acquired von Willebrand's syndrome associated with benign monoclonal gammopathy (1989) (9)
- Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding. (2022) (9)
- Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A (2016) (9)
- Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis. (2018) (9)
- First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies (2020) (9)
- Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence (2020) (9)
- Failure of DDAVP to shorten the prolonged bleeding time of two patients with congenital afibrinogenemia. (1992) (9)
- Thrombosis in Patients with Heterozygous and Homozygous Factor XII Deficiency Is not Explained by the Associated Presence of Factor V Leiden (1996) (9)
- Congenital hypofibrinogenemia associated with novel homozygous fibrinogen Aα and heterozygous Bβ chain mutations. (2015) (9)
- Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series (2017) (9)
- Erythema multiforme after intravenous immunoglobulin (1988) (8)
- von Willebrand factor multimers von Willebrand disease "Vicenza" with larger-than-normal (supranormal) (2011) (8)
- Pulmonary embolism after pregnancy in a patient with polycythemia vera (2001) (8)
- Joint replacement for the management of haemophilic arthropathy in patients with inhibitors: A long‐term experience at a single Haemophilia centre (2020) (8)
- One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B (2019) (8)
- B cell–activating factor modulates the factor VIII immune response in hemophilia A (2021) (8)
- Angiodysplasia and von Willebrand’s Disease (1994) (8)
- Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas (2011) (8)
- New approaches in the measurement of coagulation (2008) (8)
- Autosomal Recessive von Willebrand Disease Type 1 or 2 due to Homozygous or Compound Heterozygous Mutations in the von Willebrand Factor Gene (2009) (8)
- Successful use of recombinant FVIIa in combined factor V and FVIII deficiency with surgical bleeding resistant to substitutive treatment. A case report (2011) (8)
- A contribution to the pathology of acquired plasma factor XIII deficiency. (1985) (8)
- Further evidence of heterogeneity of gene defects in Italian families with factor XIII deficiency (2012) (8)
- AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years (2020) (7)
- Adult patients with the nephrotic syndrome: really at high risk for deep venous thromboembolism? Report of a series and review of the literature. (1993) (7)
- Viscosupplementation in symptomatic haemophilic arthropathy of the knee and ankle: Experience with a high molecular weight hyaluronic acid (2020) (7)
- Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation (1998) (7)
- The response of plasma von Willebrand factor to desmopressin (DDAVP) is related to the platelet levels of von Willebrand factor. (1992) (7)
- Calibration of Lyophilized Standards for Ristocetin Cofactor Activity of von Willebrand Factor (vWF) Requires vWF-Deficient Plasma as Diluent for Dose-Response Curves (1987) (7)
- Association of protein S p.Pro667Pro dimorphism with plasma protein S levels in normal individuals and patients with inherited protein S deficiency. (2007) (7)
- The Epidemiology of von Willebrand Disease (2011) (7)
- The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A (2021) (7)
- A novel factor XI missense mutation (Val371Ile) in the activation loop is responsible for a case of mild type II factor XI deficiency (2007) (6)
- Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party. (2016) (6)
- Identification of three candidate mutations causing type IIA von Willebrand disease using a rapid, nonradioactive, allele-specific hybridization method. (1993) (6)
- Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age‐matched controls (2018) (6)
- Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B (2016) (6)
- Hemophilia management: Huge impact of a tiny difference (2020) (6)
- Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy (2018) (6)
- Is a reduced intensity treatment with Rituximab effective in acquired haemophilia A? (2011) (6)
- Flow cytometry in the diagnosis of drug‐induced thrombocytopenia: Two illustrative cases (2008) (6)
- First Italian Families with Homozygous R854Q Type 2 N Von Willebrand Disease (2002) (6)
- Fibrinogen Vicenza and Genova II: Two New Cases of Congenital Dysfibrinogenemia with Isolated Defect of Fibrin Monomer Polymerization and Inhibitory Activity on Normal Coagulation (1987) (6)
- In vivo experiments indicate that relatively high platelet deposition in von Willebrand's disease 'Vicenza' is caused by normal platelet-VWF levels rather than by high VWF-multimers in plasma. (1992) (6)
- Acquired transitory factor XI inhibitor after gynaecological surgery (2008) (6)
- Fulminant sepsis in adults splenectomized for Hodgkin's disease. (1993) (5)
- Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3 (2019) (5)
- Phase 2b Trial of AMT-061 (AAV5-Padua hFIX): Translation into Humans of an Enhanced Gene Transfer Vector for Adults with Severe or Moderate-severe Hemophilia B (2019) (5)
- Grossly Abnormal Proteolysis of von Willebrand Factor (VWF) in a Patient Heterozygous for a Gene Deletion and Mutation in the Dimerization Area of VWF (2000) (5)
- Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study (2021) (5)
- Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains. (2020) (5)
- Severe factor XI deficiency in the Abruzzo region of Italy is associated to different FXI gene mutations (2008) (5)
- How I treat von Willebrand disease. (2020) (5)
- Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia. (1993) (5)
- Current and emerging biologics for the treatment of hemophilia (2019) (5)
- Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial (2020) (4)
- The bleeding phenotype in people with nonsevere hemophilia (2022) (4)
- Obstacles to Early Diagnosis and Treatment of Inherited von Willebrand Disease: Current Perspectives (2021) (4)
- Factor XI gene mutations in factor XI deficient patients of the Czech Republic (2008) (4)
- [Prevention of hemorrhage and dental treatment of patients with congenital or acquired coagulopathies]. (1997) (4)
- The effect of management models on thromboembolic and bleeding rates in anticoagulated patients: an ecological study (2019) (4)
- An unusually prolonged case of heparin-induced thrombocytopenia and disseminated intravascular coagulation. (1992) (4)
- Recurrence of the ‘deep-intronic’ FGG IVS6-320A>T mutation causing quantitative fibrinogen deficiency in the Italian population of Veneto (2009) (4)
- The von Willebrand factor (1990) (4)
- Successful treatment of neonatal "autoimmune" thrombocytopenia with high-dose intravenous immunoglobulins. (1985) (4)
- Subunit Composition of Plasma von Willebrand Factor (vWF) in Two Uremic Patients with Acquired vWF Abnormalities (1992) (4)
- Triton X contaminating platelet lysate critically affects the measurement of von Willebrand factor ristocetin cofactor activity. (1989) (4)
- Low bone mass and hypovitaminosis D in haemophilia: A single‐centre study in patients with severe and moderate haemophilia A and B (2020) (4)
- Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors (2021) (4)
- Effect of DCEP Mobilizing Regimen in in vivo Purging of PBSC Harvests in Multiple Myeloma (2004) (4)
- The Italian institutional accreditation model for Haemophilia Centres. (2014) (4)
- Albutrepenonacog alfa (Idelvion®) for the treatment of Italian patients with hemophilia B: a budget impact model (2018) (3)
- Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. (2021) (3)
- Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study (2022) (3)
- The Ser460Pro substitution of the protein S (PS) gene in rare in Italian patients with type IIa PS deficiency. (1996) (3)
- F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes (2021) (3)
- Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A (2018) (3)
- The Coagulopathy of Acute Leukemia (1992) (3)
- Prophylaxis therapy in paediatric patients with haemophilia: a survey of clinical management trends in Italy. (2015) (3)
- Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A (1989) (3)
- Recurrent life-threatening epistaxis in a child with Bernard-Soulier syndrome controlled by bilateral ligation of external carotids and ethmoidal arteries. (1987) (3)
- IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy (2022) (3)
- Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors (2022) (3)
- Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study (2020) (3)
- Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy. (2022) (3)
- Chapter 6. Von Willebrand Disease (2007) (3)
- A Prospective Evaluation of Bleeding Tendency and Efficacy of Antihemorrhagic Treatments in Patients with Increased Von Willebrand Factor (VWF) Clearance (Von Willebrand Disease Vicenza AND C1130F Mutation). (2008) (3)
- Analysis of the structural effects of four novel and a previously known mutations causing factor XI deficiency (2009) (3)
- One Year Follow-Up Study of T-Cell Subsets and Incidence of Seropositivity for HTLV-I and HTLV-III Antibodies in Patients Treated “On Demand” or Sporadically with Clotting Concentrates (1985) (3)
- Diagnosis and management of von Willebrand disease in Italy (2018) (3)
- von Willebrand disease and von Willebrand factor (2022) (3)
- ERYTHROCYTE FRAGMENTATION IN DISSEMINATED INTRAVASCULAR COAGULATION (DIC) IN ACUTE LEUKAEMIA (1985) (3)
- The higher prevalence of missense mutations in hemophilia B compared to hemophilia A could be important in determining a milder clinical phenotype in patients with severe hemophilia B (2016) (3)
- Pharmacokinetics of a new human plasma‐derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients (2019) (2)
- Combination of CLEC4M rs868875 G-Carriership and ABO O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients (2022) (2)
- Safety and effectiveness of recombinant factor XIII‐A2 in congenital factor XIII deficiency: Real‐world evidence (2022) (2)
- Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A with FVIII Inhibitors: Final Analysis (2021) (2)
- Erratum: Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy (Blood Transfusion (2014) 12 (575-98)) (2015) (2)
- Severe bleeding and absent ADP-induced platelet aggregation associated with inherited combined CalDAG-GEFI and P2Y12 deficiencies (2019) (2)
- Short and Long-Term Outcomes in Hemophilia Patients with Inhibitors Undergoing Orthopedic Prosthetic Surgery (2015) (2)
- Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians (2021) (2)
- Pharmacokinetic Evaluation of a Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency. (2008) (2)
- Histidine-rich glycoprotein changes during pregnancy in a woman with genetically transmitted high levels of the protein and thrombotic diathesis. (1993) (2)
- Stable Elevations in FIX Activity and Reductions in Annualized Bleeding Rate over up to 2 Years of Follow-up of Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy (2017) (2)
- Increased proteolysis of antithrombin III Vicenza during disseminated intravascular coagulation in acute leukemia. (1989) (2)
- Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients: a reply to a rebuttal (2012) (2)
- Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial (2019) (2)
- A novel heterozygous missense mutation (His127Arg) in a family with inherited cross-reacting material positive factor XI deficiency (2013) (2)
- Factor VIII gene (F8) mutation and inhibitor development in non-severe hemophilia A (2013) (2)
- Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies (2015) (2)
- Identification of 18 High Risk F8 Mutations for Inhibitor Development in 2,700 Non-Severe Hemophilia A Patients (2013) (2)
- Platelet ristocetin cofactor (RiCof) in patients with type I "platelet normal" von Willebrand disease correlates with plasma RiCof peak after desmopressin infusion. (1995) (2)
- Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study (2022) (2)
- 2B or not 2B: when VWF is not a good platelet friend. (2013) (2)
- No Influence of Blood Group on the Responsiveness to Desmopressin in Type I “Platelet Normal” von Willebrand’s Disease (1995) (2)
- The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors (2021) (2)
- Ex vivo experimental thrombosis in variants of von Willebrand disease. (1993) (2)
- Intracellular Retention, Enhanced Clearance, and Defective FVIII Binding Are Common Features of Von Willebrand Factor D9-D3 Domain Mutations in Patients with Von Willebrand Disease Type 1 From the European Mcmdm-1VWD Study (2012) (2)
- A novel G-toA mutation in intron-N of the protein S gene leading to abnormal RNA splicing in a patient with protein S deficiency (2003) (2)
- Thrombotic and Hemorrhagic Complications after Surgery in Patients with Essential Thrombocythemia and Polycythemia Vera. (2006) (2)
- Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. (2023) (2)
- Hemophilia A: different phenotypes may be explained by multiple and variable effects of the causative mutation in the F8 gene (2018) (2)
- Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY) (2022) (2)
- TREATMENT OF DIC ASSOCIATED WITH APL. RESPONSE (1990) (1)
- The Management of the Haemophilic Arthropathy (2017) (1)
- PRO28 EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS (2019) (1)
- Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors (2022) (1)
- Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up (2022) (1)
- Inhibitor development: The last enemy to be defeated in hemophilia A and B (2014) (1)
- Two families with combined homozygous/heterozygous factor V Leiden mutation and heterozygous G20210A factor II variant. (2000) (1)
- Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study (2019) (1)
- ON THE DISCREPANT POST‐DDAVP INCREASE OF FVIII:C AND VON WILLEBRAND FACTOR IN SOME PATIENTS WITH SEVERE VON WILLEBRAND'S DISEASE (1995) (1)
- A novel fibrinogen gamma chain mutation (gamma 239 Gln-->His) is the cause of dysfibrinogenemia Vicenza. (2005) (1)
- Outcome in moderate haemophilia: back to the past? Remarks on haemophilia A classification and treatment. (2014) (1)
- A type mutation II (Glu117stop), induction of allele-specific mRNA degradation and FXI deficiency (2005) (1)
- On the Use of Desmopressin in von Willebrand Disease (2011) (1)
- Fibrinogen survival and fibrinopeptide A in acute leukemia. (1993) (1)
- Gene Transfer with Etranacogene dezaparvovec (AAV5-Padua hFIX variant) in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial (2021) (1)
- Vonicog alfa for the treatment of von Willebrand disease (2016) (1)
- A novel fibrinogen γ chain mutation (γ 239 Gln→His) is the cause of dysfibrinogenemia Vicenza (2005) (1)
- Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results (2022) (1)
- A core set of outcome measurement tools in patients with hemophilia A systematic review of the measurement properties (1)
- Pathogenesis of the Haemophilic Arthropathy (2017) (1)
- Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia (2021) (1)
- treatment in mild hemophilia A Molecular and clinical predictors of inhibitor risk and its prevention and (2014) (1)
- Chapter 8. Von Willebrand Disease (2010) (1)
- Advances in diagnosis of von Willebrand disease (2019) (1)
- Current Management of von Willebrand’s Disease (1995) (1)
- Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe (2022) (1)
- Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study (2022) (1)
- Juvenile essential thrombocythemia: really a benign disease? (1989) (1)
- Management of Spontaneous Bleeding and Prevention of Bleeding After Dental Extractions and Other Surgical Procedures in Mild Hemophilia a and Von Willebrand’s Disease: Ten Years of Experience at the Vicenza Hemophilia and Thrombosis Center (1993) (1)
- Non-Compartment and Compartmental Pharmacokinetics, Efficacy, and Safety of Kedrion FIX concentrate. (2020) (1)
- Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy. (2022) (1)
- BLEEDING TIME IN NORMAL SUBJECTS: ITS RELATIONSHIP WITH SEX, AGE, BLOOD GROUP, HEMATOCRIT, PLATELET COUNT AND PLASMA VON WILLEBRAND FACTOR LEVEL (1987) (1)
- Idelvion For The Treatment of Hemophilia B: A Budget Impact Analysis In The Italian Setting (2017) (1)
- [Therapy with high-dose intravenous gamma globulin in the newborn infant with thrombocytopenia from passive immunization]. (1985) (1)
- A new case of passovoy defect (1992) (1)
- In fl uence of proband ’ s characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G 20210 A polymorphisms (2013) (1)
- Clinical significance of fibrinopeptide A in acute lymphocytic and non-lymphocytic leukaemia (1989) (1)
- Determinants of inhibitor development in previously treated hemophilia A patients (2015) (1)
- European Study MCMDM-1VWD phenotype in type 1 von Willebrand disease (VWD): results from the Response to desmopressin is influenced by the genotype and (2013) (1)
- The Arrival of Gene Therapy for Patients with Hemophilia A (2022) (1)
- AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirms Stable FIX Expression and Sustained Reductions in Bleeding for up to 5 Years (2021) (1)
- Use of the von Willebrand factor concentrate with low factor VIII content to manage patients with inherited von Willebrand disease requiring surgical or secondary long‐term prophylaxis: An expert opinion paper from an Italian panel (2022) (1)
- [Tooth extractions in patients with hemophilia and von Willebrand's disease]. (1987) (0)
- Preliminary characterization of a new congenital hypodysfibrinogenemia (vicenza II) and of dysfibrinogenemia genova IV (1993) (0)
- THROMBOSIS AND HEMOSTASIS Speci fi c factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations (2017) (0)
- Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age (2021) (0)
- PF802 ANTICOAGULANT THERAPY IN THROMBOCYTOPENIC PATIENTS WITH BLOOD CANCER AND CATHETER-RELATED VTE: RESULTS FROM A DELPHI CONSENSUS ON PLATELETS COUNT BELOW 50 X 109L (2019) (0)
- Eight novel mutations in FXI gene (2005) (0)
- Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A (2021) (0)
- Pharmacokinetics of a Recombinant Von Willebrand Factor in Patients with Severe Von Willebrand Disease (2015) (0)
- S297: ASSESSING THE COST-EFFECTIVENESS OF LONG-TERM PROPHYLAXIS STRATEGIES IN VON WILLEBRAND DISEASE (2022) (0)
- Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study (2022) (0)
- Safety and Longer-Term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia a or b with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial (2020) (0)
- Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project (2018) (0)
- Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project) (2018) (0)
- THROMBOSIS AND HEMOSTASIS VWF propeptide and ratios between VWF , VWF propeptide , and FVIII in the characterization of type 1 von Willebrand disease (2013) (0)
- thrombocythemia: a retrospective survey Post-surgery outcomes in patients with polycythemia vera and essential (2013) (0)
- The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms (2022) (0)
- Type II mutation (Glu117stop) causes factor XI deficiency by inducing allele specific mRNA degradation (2005) (0)
- A Two-Year Prospective Study on Bleeding Tendency In 105 Patients with Type 2 A and M Von Willebrand Disease (2010) (0)
- OPINION New development in von Willebrand disease (2013) (0)
- Ongoing developments in our understanding of haemophilia - perspectives on the therapeutic and immunogenic potential of Factor VIII (Il Ciocco - Barga (LU), 5-6 June 2015). (2015) (0)
- Laying the foundations for gene therapy in Italy for patients with haemophilia A: A Delphi consensus study (2022) (0)
- Von Willebrand disease: 80 year-old without wrinklesl (2009) (0)
- Fall Off of Factor VIII Elicited by Desmopressin Administration in Hemophiliacs and von Willebrand’s Disease Patients (1993) (0)
- Hemostatic Abnormalities in Gaucher Disease: Mechanisms and Clinical Implications (2022) (0)
- A contribution to the debate about the possible different clinical severity between hemophilia A and B (2016) (0)
- [Cost-minimization analysis of replacement therapy in the treatment of von Willebrand disease] (2016) (0)
- Aspects of clearance of VWF (2015) (0)
- Factors VIII and Von Willebrand Levels in Women Undergoing Assisted Reproduction: Are Their Levels Associated with Clinical Pregnancy Outcome? (2020) (0)
- 1 SPECIFIC FACTOR IX mRNA and PROTEIN FEATURES FAVOR DRUG-INDUCED READTHROUGH OVER RECURRENT NONSENSE MUTATIONS Short title : Determinants of drug-induced readthrough in HB (2017) (0)
- Inhibitors increase the burden of disease in nonsevere haemophilia A patients - treatment strategies to obtain hemostasis (2014) (0)
- von Willebrand's disease and hemophilia A Consistency of responses to repeated DDAVP infusions in patients with (2011) (0)
- THROMBOSIS AND HEMOSTASIS Factor VIII gene ( F 8 ) mutation and risk of inhibitor development in nonsevere hemophilia A (2013) (0)
- Multicenter Italian Study on Subcutaneous Concentrated Desmopressin (Emosint) for the in-Hospital and Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A: Outline of the Project (1993) (0)
- New opportunities in Haemophilia treatment: Efmoroctocog Alfa for patients with Haemophilia A (2022) (0)
- Pain relief with Eptacog beta in haemophilia patients with inhibitors (2023) (0)
- Variability of treatment modalities and intensity in patients with severe haemophilia A on prophylaxis: Results from the Italian national registry (2021) (0)
- Authors' reply (1994) (0)
- Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A (2023) (0)
- Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease. (2018) (0)
- RISE: Response to DDAVP In mild Hemophilia A patients: in Search for dEterminants (2013) (0)
- Women with rare bleeding disorders (2008) (0)
- Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis of the Prodeswil Study (2015) (0)
- Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients (2010) (0)
- cause of Diamond-Blackfan anemia Mutations in the erythropoietin receptor gene are not a common (2011) (0)
- Brief report Missense or splicing mutation? The case of a fibrinogen B (cid:1) -chain mutation causing severe hypofibrinogenemia (2004) (0)
- Von Willebrand Disease: Clinical Aspects and Practical Management (2014) (0)
- PRO40 Cost-Consequence Analysis of Emicizumab Prophylaxis for Severe Hemophilia a Patients without Inhibitors (2020) (0)
- THROMBOSIS AND HEMOSTASIS Hemostatic ef fi cacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease (2016) (0)
- Clinical presentation of inhibitor development in non-severe hemophilia A: Half of patients have high titer inhibitors and present with bleeding complications (2014) (0)
- HOPE-B: Study Design of a Phase III trial of an Investigational Gene Therapy AMT-061 in Subjects with Severe or Moderately Severe Hemophilia B (2019) (0)
- The International Classification of Functioning as a framework for development of a core set of musculoskeletal measures in hemophilia (2015) (0)
- FIBRINOGEN GENOVA III: A NEW CONGENITAL DYSFIBRINOGENEMIA WITH BLEEDING DIATHESIS AND DEFECTIVE LYSIS BY PLASMIN (1987) (0)
- The POWER app: design and usability testing of a mobile app for the collection of patient-reported outcome data in type A haemophilia (Preprint) (2020) (0)
- Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors (2022) (0)
- HOMOZYGOUS FACTOR XII CONGENITAL DEFICIENCY: STUDY OF 10 NEW FAMILIES. (1987) (0)
- 0.10b Low-molecular-weight heparin for prevention of obstetric complications in carriers of factor V Leiden or PT-G20210A mutation (2011) (0)
- Intrinsic and method-induced variation of the bleeding time and related parameters (2007) (0)
- Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting (2022) (0)
- Translational readthrough at F8 nonsense variants in the factor VIII B domain contributes to residual expression and lowers inhibitor association (2022) (0)
- Genetically defined protein S (PS) deficiency is associated with venous thrombosis (2003) (0)
- Reply to: [Factor XI mutation and the origin of Ashkenazi Jews. Haematologica 2008; 93:e59] (2008) (0)
- Mild and Moderate Hemophilia A: Neglected Conditions, Still with Unmet Needs (2023) (0)
- Reduced Von Willebrand Factor Secretion Is Associated with Loss of Weibel-Palade Formation (2010) (0)
- How I treat How I treat von Willebrand disease (2009) (0)
- Von Willebrand disease : 80 year-old without wrinkles (2007) (0)
- Clinical, economic, and health‐related quality of life burden associated with von Willebrand disease in adults and children: Systematic and targeted literature reviews (2022) (0)
- SAT0648 Coxalgia in hemophilic patients. sonographic evaluation of a not target joint (2018) (0)
- P69. Porcine factor VIII by continuous infusion in patients with haemophilia A and inhibitors (1996) (0)
- The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both (2000) (0)
- Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience (2023) (0)
- Prophylaxis with recombinant von Willebrand factor (rVWF) in patients with type 3 von Willebrand disease (VWD): results of a post hoc analysis from a phase 3 trial. (2023) (0)
- Comment on Casari et al , page 2893 2 B or not 2 B : when VWF is not a good platelet friend (2013) (0)
- Factor XIII deficiency type I: some unresolved issues (1992) (0)
- A Poor Response to Desmopressin Is Observed in Patients with Mild Hemophilia a and No Detectable FVIII Mutation. (2008) (0)
- Clinical efficacy and safety of DDAVP with or without tranexamic acid in inherited VWD: final results of the prospective and international study on 229 patients (2013) (0)
- von Willebrand Disease "Vicenza" With Larger-Than-Normal (Supranormal) von (2016) (0)
- Von Willebrand Factor antigen and age explain variation in baseline FVIII: C among nonsevere hemophilia A patients with the same F8 genotype (Arg593Cys and Asn618Ser) (2014) (0)
- Type 2B “Malmo/New York” Is Not So Rare among Italian Patients with von Willebrand Disease: The Role of P1266L/Q Mutations of the von Willebrand Factor Gene in Seven Cases. (2007) (0)
- Safety and Efficacy of Recombinant Factor XIII (FXIII) in Patients with Congenital FXIII A-Subunit Deficiency, Results from the Mentor™2 Trial (2016) (0)
- Inherited thrombophilic syndromes: Experience of a department of hematology (1993) (0)
- Abstract (2003) (0)
- Comparison of von Willebrand factor platelet‐binding activity assays: ELISA overreads type 2B with loss of HMW multimers (2020) (0)
- In-vitro expression and functional characterization of four mutations causing factor XI deficiency (2005) (0)
- Multicenter Evaluation of a New Concentrated Desmopressin Preparation (Emosint) Administered Intravenously or Subcutaneously: Analysis of Biological Responses and Side-Effects in 49 Patients with Hemophilia a and Von Willebrand’s Disease (1993) (0)
- disease Epidemiological investigation of the prevalence of von Willebrand's (2011) (0)
- EE120 Real-World Utilisation of Damoctocog Alfa Pegol in Adults With Haemophilia A: Second Interim Analysis of the HEM-POWR Observational Study (2022) (0)
- Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up (2023) (0)
- PROSPECTIVE STUDY OF THE IMMUNOLOGICAL MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN HAEMOPHILIA A PATIENTS WITH INHIBITORS (2017) (0)
- PRO53 Economic IMPACT of Emicizumab Prophylaxis for Hemophilia a with and without Inhibitors (2020) (0)
- Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients. (2009) (0)
- theorem approach Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes (2009) (0)
- A BAYESIAN APPROACH TO THE DIAGNOSIS OF TYPE 1 VON WILLEBRAND DISEASE (2007) (0)
- F8 Gene Mutations and ITT Response in the Italian Cohort of Haemophilia A Patients with Inhibitors. (2005) (0)
- von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. (2023) (0)
- Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors (2022) (0)
- Desmopressin-induced thrombocytopenia in von Willebrand disease patients with the Arg611His mutation in the A1 domain of von Willebrand factor. (1996) (0)
- Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B (2023) (0)
- von Willebrand Factor: A Prima Ballerina on Two Different Stages P.M. Mannucci New Perspectives on von Willebrand Factor Functions in Hemostasis and Thrombosis (2005) (0)
- CLINICAL AND MOLECULAR PREDICTORS OF THROMBOCYTOPENIA AND RISK OF BLEEDING IN PATIENTS WITH VON WILLEBRAND DISEASE TYPE 2B: A COHORT STUDY OF 67 PATIENTS Running title: Thrombocytopenia and bleeding risk in VWD 2B (2008) (0)
- Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study (2018) (0)
- First factor IX mutations in Albanian hemophilia B patients (2008) (0)
- pa-Clinical manifestations and management of Gaucher disease (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Giancarlo Castaman?
Giancarlo Castaman is affiliated with the following schools:
